OSBPL3 and glioblastoma: Subsequent research on the genes and molecular pathways associated with OS improvement revealed two possible associated genes, FM04 and OSBPL3. In GBM patients treated with a combination of BEV and CCNU, a higher FM04/OSBPL3 expression level was associated with a significantly increased mOS (6.1 vs 12.4 months, P < 0.0001) (Table 1).27